Skip to main content
. 2017 Mar 13;12(5):718–726. doi: 10.2215/CJN.10471016

Table 2.

Multivariate regression analyses of predictors in-hospital mortality, postinterventional bleeding, and permanent pacemaker implantation (n=28,715)

Predictors In-Hospital Mortality Bleeding PPI
Odds Ratio 95% CI P Value Odds Ratio 95% CI P Value Odds Ratio 95% CI P Value
Without renal disease 1 1 1
CKD stage 1 0.83 0.42 to 1.63 0.58 0.81 0.44 to 1.50 0.50 0.66 0.42 to 1.05 0.08
CKD stage 2 0.85 0.69 to 1.05 0.14 0.92 0.76 to 1.11 0.39 0.91 0.80 to 1.04 0.16
CKD stage 3 1.13 1.00 to 1.27 0.04 1.10 0.99 to 1.23 0.08 0.99 0.92 to 1.07 0.81
CKD stage 4 1.31 1.06 to 1.61 0.01 1.43 1.18 to 1.72 <0.001 0.97 0.83 to 1.14 0.75
CKD stage 5 1.71 1.35 to 2.17 <0.001 1.82 1.47 to 2.24 <0.001 1.19 0.98 to 1.44 0.08
TF-TAVI (instead of TA-TAVI) 0.62 0.56 to 0.68 <0.001 0.52 0.48 to 0.58 <0.001 2.71 2.49 to 2.95 <0.001
Women 0.88 0.79 to 0.98 0.02 1.08 0.98 to 1.20 0.12 0.88 0.82 to 0.95 0.001
Age 1.00 0.99 to 1.01 0.58 0.98 0.97 to 0.98 <0.001 1.01 1.00 to 1.02 0.03
EuroSCORE 1.03 1.02 to 1.03 <0.001 1.02 1.02 to 1.03 <0.001 1.00 1.00 to 1.01 0.23
Aortic valve stenosis 0.61 0.51 to 0.74 <0.001 0.73 0.61 to 0.87 <0.001 0.83 0.72 to 0.95 <0.01
Combined aortic valve diseases 0.51 0.42 to 0.62 <0.001 0.66 0.55 to 0.80 <0.001 0.93 0.81 to 1.08 0.34
NYHA 2 0.54 0.42 to 0.69 <0.001 0.67 0.55 to 0.82 <0.001 1.04 0.93 to 1.17 0.51
NYHA 3 or 4 1.45 1.31 to 1.61 <0.001 1.33 1.21 to 1.45 <0.001 1.09 1.02 to 1.17 0.01
CAD 1.07 0.96 to 1.19 0.22 1.05 0.96 to 1.16 0.29 1.02 0.95 to 1.09 <0.01
Hypertension 0.70 0.63 to 0.77 <0.001 0.78 0.71 to 0.86 <0.001 1.03 0.96 to 1.10 0.37
Previous MI (within 0–4 mo) 0.67 0.45 to 0.99 0.04 0.79 0.57 to 1.11 0.18 0.79 0.60 to 1.03 0.08
Previous MI (within 4–12 mo) 1.01 0.59 to 1.72 0.98 1.07 0.66 to 1.73 0.78 0.91 0.63 to 1.32 0.63
Previous MI (after 12 mo) 1.07 0.85 to 1.33 0.58 0.83 0.66 to 1.04 0.11 0.82 0.69 to 0.97 0.02
Previous CABG 0.97 0.77 to 1.23 0.83 0.43 0.35 to 0.53 <0.001 0.60 0.51 to 0.70 <0.001
Previous cardiac surgery 0.76 0.59 to 0.96 0.02 1.24 1.02 to 1.51 0.03 1.56 1.34 to 1.83 <0.001
Peripheral vascular disease 1.00 0.85 to 1.16 0.96 1.03 0.90 to 1.19 0.64 0.97 0.95 to 1.09 0.63
Carotid disease 0.77 0.63 to 0.95 0.01 1.07 0.90 to 1.28 0.41 1.01 0.87 to 1.17 0.86
COPD 0.88 0.76 to 1.02 0.09 0.88 0.77 to 1.00 0.05 0.99 0.90 to 1.09 0.83
Pulmonary hypertension 0.74 0.63 to 0.86 <0.001 0.75 0.65 to 0.86 <0.001 1.02 0.92 to 1.13 0.69
Atrial fibrillation 1.13 1.02 to 1.25 0.02 1.30 1.19 to 1.43 <0.001 1.20 1.12 to 1.27 <0.001
Diabetes 1.04 0.93 to 1.15 0.49 0.99 0.90 to 1.09 0.82 1.08 1.01 to 1.15 0.03

Please note that, in comparison with the data shown in the other tables, one procedure was excluded from the multivariate logistic regression analyses due to incomplete information regarding the covariates. PPI, permanent pacemaker implantation; 95% CI, 95% confidence interval; TF-TAVI, transfemoral transcatheter aortic valve implantation; TA-TAVI, transapical transcatheter aortic valve implantation; EuroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association; CAD, coronary artery disease; MI, myocardial infarction; CABG, coronary artery bypass graft surgery; COPD, chronic obstructive lung disease.